RGBPP.PFD (Regen BioPharma) Scaled Net Operating Assets : -25.88 (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Regen BioPharma Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Regen BioPharma's operating assets for the quarter that ended in Sep. 2024 was $0.18 Mil. Regen BioPharma's operating liabilities for the quarter that ended in Sep. 2024 was $4.58 Mil. Regen BioPharma's Total Assets for the quarter that ended in Jun. 2024 was $0.17 Mil. Therefore, Regen BioPharma's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was -25.88.

Regen BioPharma Scaled Net Operating Assets Historical Data

The historical data trend for Regen BioPharma's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma Scaled Net Operating Assets Chart

Regen BioPharma Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Scaled Net Operating Assets

Get a 7-Day Free Trial

-47.78

-86.42

-5.62

-7.99

-12.43

Regen BioPharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Scaled Net Operating Assets	Get a 7-Day Free Trial															-15.68	-13.14	-28.50	-31.92	-25.88

Competitive Comparison of Regen BioPharma's Scaled Net Operating Assets

For the Biotechnology subindustry, Regen BioPharma's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regen BioPharma's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's Scaled Net Operating Assets falls into.

Regen BioPharma Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Regen BioPharma's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Sep. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Sep. 2024 )
=	(Operating Assets (A: Sep. 2024 )	-	Operating Liabilities (A: Sep. 2024 ))	/	Total Assets (A: Sep. 2023 )
=	(0.177	-	4.577)	/	0.354
=	-12.43

where

	Operating Assets		(A: Sep. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	0.178	-	0.001
=	0.177

	Operating Liabilities		(A: Sep. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	5.372	-	0	-	0.795
=	4.577

Regen BioPharma's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Sep. 2024 )
=	(Operating Assets (Q: Sep. 2024 )	-	Operating Liabilities (Q: Sep. 2024 ))	/	Total Assets (Q: Jun. 2024 )
=	(0.177	-	4.577)	/	0.17
=	-25.88

where

	Operating Assets		(Q: Sep. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	0.178	-	0.001
=	0.177

	Operating Liabilities		(Q: Sep. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	5.372	-	0	-	0.795
=	4.577

Regen BioPharma Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Regen BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBPP.PFD) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

RGBP:USA

Address

4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942

Website

https://www.regenbiopharmainc.com

Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.